Advertisement

National and International Guidelines for Overactive Bladder

Chapter
  • 396 Downloads

Abstract

Overactive bladder (OAB) syndrome is an extremely prevalent and bothersome condition. Various providers from many fields, including primary care, geriatrics, neurology, gynecology, and urology, are involved in the diagnosis and management of a wide range of patients who present with symptoms of OAB. Several urologic, urogynecologic, geriatric societies and other organizations have developed guidelines for the evaluation and pharmacologic treatment of OAB. Guidelines are developed to facilitate the care of “index” patients by making recommendations based on grading the evidence in the current literature, with the goal of avoiding inconsistencies and biases. This chapter aims to review the current national and international guidelines on the evaluation and treatment of OAB. Generally, the guidelines agree with regard to recommendations for a basic initial evaluation with a limited role for invasive testing in the uncomplicated patient and conservative treatments for first-line therapy and pharmacotherapy as effective second-line therapy. There are slightly more heterogeneous recommendations for invasive therapies for OAB. This chapter reviews the recommendations relating to pharmacotherapy specifically.

Keywords

Overactive bladder Urgency Urgency urinary incontinence Urinary bladder Detrusor overactivity Guidelines 

References

  1. 1.
    Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57(6):1044–50.CrossRefGoogle Scholar
  2. 2.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMedGoogle Scholar
  3. 3.
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.PubMedGoogle Scholar
  4. 4.
    Syan R, Brucker BM. Guideline of guidelines: urinary incontinence. BJU Int. 2016;117(1):20–33.CrossRefGoogle Scholar
  5. 5.
    The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1979;121(9):1193–254.Google Scholar
  6. 6.
    OCEBM Levels of Evidence Working Group. The Oxford levels of evidence 2. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 19 June 2018.
  7. 7.
    Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document). Oxford Centre for Evidence-Based Medicine. https://www.cebm.net/index.aspx?o=5653 (2011). Accessed 19 June 2018.
  8. 8.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. 2012; amended 2014. http://www.auanet.org/guidelines/overactive-bladder-(oab)-(aua/sufu-guideline-2012-amended-2014). Accessed 19 June 2018.
  9. 9.
    Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th ed. Bristol: ICI-ICS. International Continence Society; 2017.Google Scholar
  10. 10.
    National Institute for Health and Care Excellence. Urinary incontinence in women: the management of urinary incontinence in women. CG171. Published 2013; last updated 2015. http://www.ncbi.nlm.nih.gov/pubmed/25340217. Accessed 19 June 2018.
  11. 11.
    National Institute for Health and Care Excellence. Mirabegron for treating symptoms of overactive bladder. Technology appraisal guidance (TA290). Published 26 June 2013. https://www.nice.org.uk/guidance/ta290. Accessed 19 June 2018.
  12. 12.
    Committee on Practice Bulletins—Gynecology and the American Urogynecologic Society. Urinary incontinence in women. Female Pelvic Med Reconstr Surg. 2015;21(6):304–14.CrossRefGoogle Scholar
  13. 13.
    Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU guidelines on assessment and nonsurgical Management of Urinary Incontinence. Eur Urol. 2018;73(4):596–609.CrossRefGoogle Scholar
  14. 14.
    European Association of Urology. Guidelines. Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Hermann TRW, et al. Treatment of Non-neurogenic Male LUTS. First published in 2000; updated in 2017. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#1_4. Accessed 19 June 2018.
  15. 15.
    Corcos J, Przydacz M, Campeau L, Gray G, Hickling D, Honeine C, et al. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142–73.CrossRefGoogle Scholar
  16. 16.
    Geoffrion R; Urogynaecology Committee. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can. 2012;34(11):1092–1101.Google Scholar
  17. 17.
    Tse V, King J, Dowling C, English S, Gray K, Millard R, et al. Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) guidelines on the management of adult non-neurogenic overactive bladder. Br J Urol. 2016;117(1):34–47.CrossRefGoogle Scholar
  18. 18.
    Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Shekelle P. Clinical guidelines Committee of the American College of Physicians. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(10):429–40.CrossRefGoogle Scholar
  19. 19.
    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  20. 20.
    Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007;(4):CD003190.Google Scholar
  21. 21.
    Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4):CD003781.Google Scholar
  22. 22.
    Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011;(12):CD005493.Google Scholar
  23. 23.
    Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429.PubMedGoogle Scholar
  24. 24.
    Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev. 2017;10:CD012059.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of UrologyMedical University of South CarolinaCharlestonUSA

Personalised recommendations